This is an archived event!

Some of the information on this page like registration links or contact information might be out of date.

Event

Seminar: Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

December 13, 2018 : 12:00pm - 1:00pm PDT

MCB 101

Dr. Marzinzik has been involved in a number of drug discovery projects over the years, including development of bone targeting agents, kinase inhibitors, and cancer treatments. He will share with us an instructive story about the discovery of Asciminib, which is currently in Phase III clinical trials for treatment of CML.

Event Details

Medicinal chemist Dr. Andreas Marzinzik, who is a Director and a Leading Scientist at Novartis Global Discovery in Basel, is giving a special seminar on Thursday, December 13, 2018 at 12PM on the UPC campus in MCB 101.

Dr. Marzinzik has been involved in a number of drug discovery projects over the years, including development of bone targeting agents, kinase inhibitors, and cancer treatments. He will share with us an instructive story about the discovery of Asciminib, which is currently in Phase III clinical trials for treatment of CML. 

Seminar-Discovery-of-Asciminib-ABL001-an-Allosteric-Inhibitor-of-the-Tyrosine-Kinase-Activity-of-BCR-ABL1.png#asset:4574

Contact Information

fokin@usc.edu

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.